Edition:
United Kingdom

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

134.93USD
16 Feb 2018
Change (% chg)

$-1.18 (-0.87%)
Prev Close
$136.11
Open
$136.38
Day's High
$139.22
Day's Low
$134.77
Volume
150,250
Avg. Vol
178,942
52-wk High
$169.58
52-wk Low
$112.15

Select another date:

Fri, Feb 16 2018

BRIEF-United Therapeutics Settles Patent Litigation With Actavis Laboratories FL

* UNITED THERAPEUTICS ANNOUNCES SETTLEMENT OF PATENT LITIGATION WITH ACTAVIS LABORATORIES FL, INC. RELATING TO ORENITRAM

BRIEF-Celularity Announces Formation Of Co With $250 Mln In Funding From Celgene, United Therapeutics, Others

* ‍CELULARITY ANNOUNCES $250 MILLION IN FUNDING TO DELIVER TREATMENTS FOR CANCER, INFLAMMATORY AND DEGENERATIVE DISEASES, AND FUNCTIONAL REGENERATION​

BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs

* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS

United Therapeutics to pay $210 million to resolve U.S. kickback probe

BOSTON United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

UPDATE 2-United Therapeutics to pay $210 mln to resolve U.S. kickback probe

BOSTON, Dec 20 United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

United Therapeutics to pay $210 mln to resolve U.S. kickback probe

BOSTON, Dec 20 United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* ‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​

BRIEF-United Therapeutics Corp reports third quarter 2017 financial results

* United Therapeutics Corporation reports third quarter 2017 financial results

BRIEF-United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

* United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

Select another date: